Press release

New data for simeprevir will be presented at EASL's International Liver Congress™ 2017

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that new clinical data for simeprevir, an NS3/4A protease inhibitor for the treatment of hepatitis C virus infection, will be presented by our partner Janssen Sciences Ireland UC (Janssen) in conjunction with The International Liver Congress™ 2017 of the European Association for the Study of the Liver (EASL) in Amsterdam, on 19-23 April.

A total of four presentations will be made, including one oral presentation. The presentations will cover preclinical and clinical data on the triple combination of simeprevir, odalasvir and AL-335, as well as data on the efficacy, safety and tolerability of simeprevir used as a component of various combination therapies in a number of different adult patient populations.

Data presented at the International Liver Congress™ 2017 include:

Oral Presentation:
Abstract PS-153

Short duration treatment with AL-335 and odalasvir, with or without simeprevir, in treatment naïve patients with hepatitis C infection with or without cirrhosis.
Ed Gane, Catherine Stedman, Matthew McClure, David Apelian, Chris Westland, Jennifer Vuong, Megha Patel, Thomas Kakuda, Sushmita Chanda, Lawrence Blatt, Leo Beigelman, David Smith, John Fry

Poster Presentations:
Abstract FRI-276

In vitro virology profile of the 3 direct-acting antiviral combination of AL-335, odalasvir and simeprevir.
: Leen Vijgen, Bart Fevery, Andreas Jekle, Kenneth Shaw, Hua Tan, Oliver Lenz, Julian Symons, Sandra De Meyer

Abstract THU-281

Low rate of drug-drug interaction management during interferon-free simeprevir therapy - an integrated analysis of interventional and observational clinical studies.
: Fiona Marra, Christoph Höner zu Siederdissen, Saye Khoo, Markus Cornberg, Michael Schlag, Sivi Ouwerkerk-Mahadevan, Ceyhun Bicer, Isabelle Lonjon-Domanec, Wolfgang Jessner, Maria Beumont-Mauviel, Ronald Kalmeijer, David Back

Abstract FRI-249

Efficacy and safety of simeprevir-containing hepatitis C therapy in patients on opiate substitution therapy.
: John Dillon, Stefan Mauss, Catherine Nalpas, Ceyhun Bicer, Michael Schlag, Isabelle Lonjon-Domanec, Wolfgang Jessner, Maria Beumont-Mauviel, Ronald Kalmeijer

Details of all presentations for The International Liver Congress™ 2017 are available at:

For further information, please contact:
Richard Bethell, CSO Medivir AB, mobile +46 (0)72-704 3211

Ola Burmark, CFO Medivir AB, mobile: +46 (0) 725 480 580

About Medivir
Medivir develops innovative pharmaceutical products for the treatment of cancer. The company specialises in protease inhibitor research and nucleotide/nucleoside science and conducts research in all stages of the drug development process, from original idea to clinical phase III studies. Its development work is done both in-house and through partnerships.